$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Assessment of Vertebral Left Atrial Size and C-reactive Protein in Dogs With Myxomatous Mitral Valve Disease 원문보기

Journal of veterinary clinics = 한국임상수의학회지, v.38 no.1, 2021년, pp.16 - 20  

Hwang, Sun-Hwee (College of Veterinary Medicine, Chungnam National University) ,  Song, Kun Ho (College of Veterinary Medicine, Chungnam National University)

Abstract AI-Helper 아이콘AI-Helper

Recently, a new method of evaluating left atrial size called vertebral left atrial size (VLAS) was introduced in dogs. Total 155 dogs were examined at the Veterinary Medical Teaching Hospital of Chungnam National University. In this study, myxomatous mitral valve disease (MMVD) stage and VLAS showed...

주제어

AI 본문요약
AI-Helper 아이콘 AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

문제 정의

  • In a previous study, VLAS was measured in several breeds of healthy dogs (26). In our study, we focused on the VLAS values of three breeds with a predisposition to MMVD in South Korea. When we evaluated each breed, the median VLAS value of the Maltese was 2.
본문요약 정보가 도움이 되었나요?

참고문헌 (26)

  1. Abbott JA. 2008. Acquired valvular disease. In: Manual of canine and feline cardiology. 4th ed. St. Louis: Elsevier Sounders. 2008: 110-138. 

  2. Andreasova T, Vranova J, Vondrakova D, Sedlackova L, Zakostelska ZJ, Neuzil P, Malek F. Role of biomarkers of cardiac remodeling, myofibrosis, and inflammation in assessment of disease severity in euvolemic patients with chronic stable heart failure. J Int Med Res 2020; 48: 1-12. 

  3. Apple SM, Menciotti G, Braz-Ruivo L, Crosara S, Haggstrom J, Borgarelli M. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study. Aust Vet J 2016; 94: 324-328. 

  4. Borgarelli M, Crosara S, Lamb K, Savarino P, La Rosa G, Tarducci A Haggstrom J. Survival javascript:checkRefBr('', 'next');characteristics and prognostic variables of dogs with preclinical chronic degenerative mitral valve disease attributable to myxomatous degeneration. J Vet Intern Med 2012; 26: 69-75. 

  5. Borgarelli M, Haggstrom J. Canine degenerative myxomatous mitral valve disease: natural history, clinical presentation and therapy. Vet Clin North Am Small Anim Pract 2010; 40: 651-663. 

  6. Boswood A, Haggstrom J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmari V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. J Vet Intern Med 2016; 30: 1765-1779. 

  7. Buchanan JW, Bucheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc 1995; 206: 194-199. 

  8. Ceron JJ, Eckersall PD, Martynez-Subiela S. Acute phase proteins in dogs and cats: current knowledge and future perspectives. Vet Clin Pathol 2005; 34: 85-99. 

  9. Chetboul V, Tissier R. Echocardiographic assessment of canine degenerative mitral valve disease. J Vet Cardiol 2012; 14: 127-148. 

  10. Cornell CC, Kittleson MD, Della Torre P, Haggstrom J, Lombard CW, Pedersen HD, Vollmar A, Wey A. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004; 18: 311-321. 

  11. Detweiler DK, Patterson DF. The prevalence and types of cardiovascular disease in dogs. Ann N Y Acad Sci 1965; 127: 481-516. 

  12. Diana A, Guglielmini C, Pivetta M, Sanacore A, Di Tommaso M, Lord PF, Cipone M. Radiographic features of cardiogenic pulmonary edema in dogs with mitral regurgitation: 61 cases (1998-2007). J Am Vet Med Assoc 2009; 235: 1058-1063. 

  13. Domanjko Petric A, Lukman T, Verk B, Nemec Svete A. Systemic inflammation in dogs with advanced-stage heart failure. Acta Vet Scand 2018; 60: 20. 

  14. Elster SK, Braunwald E, Wood HF. A study of C-reactive protein in the serum of patients with congestive heart failure. Am Heart J 1956; 51: 533-541. 

  15. Haggstrom J, Lord PF, Hoglund K, Ljungvall I, Jons O, Kvart C, Hansson K. Short-term h emodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure. J Vet Intern Med 2013; 27: 1452-1462. 

  16. Keene BW, Atkins CE, Bonagura JD, Fox PR, Haggstrom J, Fuentes VL, Oyama MA, Rush JE, Stepien R, Uechi M. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med 2019; 33: 1127-1140. 

  17. Kim SH, Seo KW, Song KH. An assessment of vertebral left atrial size in relation to the progress of myxomatous mitral valve disease in dogs. J Vet Clin 2020; 37: 9-14. 

  18. Lamb CR, Wikeley H, Boswood A, Pfeiffer DU. Use of breed-specific ranges for the vertebral heart scale as an aid to the radiographic diagnosis of cardiac disease in dogs. Vet Rec 2001; 148: 707-711. 

  19. Malcolm EL, Visser LC, Phillips KL, Johnson LR. Diagnostic value of vertebral left atrial size as determined from thoracic radiographs for assessment of left atrial size in dogs with myxomatous mitral valve disease. J Am Vet Med Assoc 2018; 253: 1038-1045. 

  20. Mikawa S, Nagakawa M, Ogi H, Akabane R, Koyama Y, Sakatani A, Ogawa M, Miyakawa H, Shigemoto J, Tokuriki T, Toda N, Miyagawa Y, Takemura N. Use of vertebral left atrial size for staging of dogs with myxomatous valve disease. J Vet Cardiol 2020; 30: 92-99. 

  21. Reimann MJ, Ljungvall I, Hillstrom A, Moller JE, Hagman R, Falk T, Hoglund K, Haggstrom J, Olsen LH. Increased serum C-reactive protein concentrations in dogs with congestive heart failure due to myxomatous mitral valve disease. Vet J 2016; 209: 113-118. 

  22. Reynolds CA, Brown DC, Rush JE, Fox PR, Nguyenba TP, Lehmkuhl LB, Gordon SG, Kellihan HB, Stepien RL, Lefbom BK, Meier CK, Oyama MA. Prediction of first onset of congestive heart failure in dogs with degenerative mitral valve disease: the PREDICT cohort study. J Vet Cardiol 2012; 14: 193-202. 

  23. Rishniw M, Erb HN. Evaluation of four 2-dimensional echocardiographic methods of assessing left atrial size in dogs. J Vet Intern Med 2000; 14: 429-435. 

  24. Serres FJ, Chetboul V, Tissier R, Carlos Sampedrano C, Gouni V, Nicolle AP, Pouchelon JL. Doppler echocardiography-derived evidence of pulmonary arterial hypertension in dogs with degenerative mitral valve disease: 86 cases (2001-2005). J Am Vet Med Assoc 2006; 229: 1772-1778. 

  25. Strohm LE, Visser LC, Chapel EH, Drost WT, Bonagura JD. Two-dimensional, long-axis echocardiographic ratios for assessment of left atrial and ventricular size in dogs. J Vet Cardiol 2018; 20: 330-342. 

  26. Vezzosi T, Puccinelli C, Tognetti R, Pelligra T, Citi S. Radiographic vertebral left atrial size: A reference interval study in healthy adult dogs. Vet Radiol Ultrasound 2020; 61: 507-511. 

관련 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로